Disease Overview：Small Intestinal Stromal Tumor（SIST）
Small intestinal gastrointestinal stromal tumor (GIST) is a rare mesenchymal neoplasm arising from the interstitial cells of Cajal—pacemaker cells regulating gastrointestinal motility. Accounting for approximately 5–10% of all GISTs, small bowel GISTs most commonly occur in the jejunum or ileum and often present with nonspecific symptoms such as abdominal pain, gastrointestinal bleeding, anemia, or incidental findings on imaging. Diagnosis relies on endoscopic evaluation, contrast-enhanced CT or MRI, and definitive histopathological confirmation with immunohistochemical staining for KIT (CD117) and DOG1. Risk stratification follows the modified NIH or AFIP criteria, guiding management decisions ranging from surgical resection for localized disease to adjuvant or advanced-line tyrosine kinase inhibitor therapy (e.g., imatinib, sunitinib) for metastatic or high-risk cases.
China offers distinct advantages for international patients seeking care for small intestinal GIST. The country hosts nationally accredited GIST specialty centers with multidisciplinary teams experienced in complex laparoscopic and robotic-assisted resections, precision molecular profiling, and personalized TKI sequencing. Advanced imaging modalities—including 3T MRI with diffusion-weighted sequences and PET-CT—are widely available in tier-1 hospitals. Clinical outcomes align with international benchmarks: five-year recurrence-free survival exceeds 75% for intermediate-risk resected cases, supported by robust real-world evidence from institutions like Peking Union Medical College Hospital and Fudan University Shanghai Cancer Center. Treatment costs in China are typically 40–60% lower than in the US or Western Europe, without compromising quality—imatinib generics, for instance, cost under USD 100/month versus USD 1,200+ abroad.
As a dedicated medical tourism agency, we facilitate seamless access to these resources for international patients: verifying hospital credentials, coordinating appointments with GIST-dedicated surgeons and oncologists, providing itemized, transparent pricing in advance, arranging visa support, accommodation, and multilingual clinical liaison services—all tailored to optimize clinical outcomes and reduce logistical burden.
Medical Treatment Guide
Treatment Options & Itemized Cost Breakdown: Small Bowel Gastrointestinal Stromal Tumor (GIST)
Non-Surgical / Medical Management
*Indicated for unresectable, metastatic, or adjuvant therapy post-resection; requires KIT/PDGFRA mutation testing.*
- •Imatinib (first-line): 400–800 mg/day oral. *Eligibility*: Confirmed KIT exon 11 mutation; ECOG PS ≤2.
- Monthly monitoring (CBC, LFTs, abdominal CT/MRI): ¥1,200 ($167) - Mutation testing (NGS panel): ¥2,500 ($348)
- •Sunitinib (second-line): 50 mg/day × 4 weeks on/2 weeks off.
- Cardiac echo + thyroid function panel: ¥850 ($118)
- •Regorafenib (third-line): 160 mg/day.
- Dermatology consult + hand-foot syndrome management: ¥300 ($42)
Surgical / Interventional Options
*Eligibility: Localized, resectable tumor; no distant metastasis; adequate cardiopulmonary reserve.*
- •Laparoscopic small bowel resection + lymphadenectomy:
- Pre-op workup (EKG, chest X-ray, enhanced CT abdomen/pelvis, bowel prep kit): ¥2,100 ($292)
- •Open resection (for tumors >10 cm or adherent to adjacent organs):
- Intraoperative frozen section + margin assessment: ¥1,800 ($250)
- •Robotic-assisted resection (limited centers):
Special / Complex Condition Management
- •Locally advanced unresectable GIST (neoadjuvant imatinib):
- •Liver-limited metastases (resection + ablation):
- •Peritoneal carcinomatosis (cytoreductive surgery + HIPEC):
Quick Selection Guide
- •<60 years, localized, no comorbidities: Laparoscopic resection ($3,900–$5,850) — optimal curative intent.
- •≥65 years, moderate COPD/CKD, small asymptomatic lesion (<3 cm): Active surveillance + 3-month CT ($167 per scan) — avoids surgical risk.
- •Metastatic, KIT-mutated, budget < $5,000/year: Generic imatinib + public hospital subsidy ($390/month) — standard first-line.
- •Unresectable with rapid progression, budget > $12,000: Neoadjuvant imatinib → delayed resection ($4,450–$9,040) — improves R0 rate.
- •Refractory after 3 TKIs, ECOG 1–2: Clinical trial enrollment (no patient cost at Grade 3A sites) — access to avapritinib/ripretinib.
Pricing & Service Differences: International / VIP Dept vs. Regular Clinic
International Medical Services (IMS / VIP Departments) at Grade-3A public hospitals and private international clinics operate under self-regulated VIP fee schedules. Fees are higher than standard public clinics (which are subsidized solely for domestic citizens and do not accept overseas insurances). In exchange, international patients receive 6 exclusive medical privileges:
Recommended Hospitals
Explore selected Grade 3A public hospitals in China with rich clinical experience for this condition:
🌴 Recommended Small Intestinal Stromal Tumor Medical Vacation Packages
Curated transparent all-inclusive packages combining Small Intestinal Stromal Tumor treatment with China top medical destinations:
